BioSpace News Archive

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 7,258,065 shares of common stock of the Company, at a price to the public of $3.10 per share, less underwriting discounts and commissions. The closi

INFINITY ANGIOPLASTY BALLOON CO., announced today that its innovative PRECISION ANGIOPLASTY™ balloon platform – INFINITY ANGIOPLASTY BALLOON CATHETER™ has successfully completed First-in-Human clinical trial.

Biosero, Inc. and TetraScience, Inc. announced they will integrate data glyphs, instruments and robotic sensors with the cloud-native Tetra Data Platform using Green Button Go™ Automation Scheduling Software.

This Hanukkah Pack will be Available Starting November 26, 2020 and will be Strictly Limited to 613 Units Anticipated Price per Unit: $61.30 USD

SIRIO – a leading nutraceutical contract development and manufacturing organisation (CDMO) – has completed a new ‘smart factory’ at its Ma’anshan site, with Internet of Things (IoT) enabled automated processes and monitoring, intelligent distribution robotics and Artificial intelligence (AI).

Augmedix, Inc., the ambient, mobile, real-time, and remote documentation specialist for doctors and health systems, yesterday announced financial results for its third quarter ended September 30, 2020.

Abzyme Therapeutics LLC, a biotech company focused on developing antibodies for diagnostic and therapeutic applications, has filed a patent application entitled “Antibodies Binding to Human CD3 at Acidic pH”, USPTO number 63/109,005. This patent application is an important step forward for Abzyme Therapeutics solidifying its intellectual property position in the field of therapeutic antibody development. Monoclon

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.65 per share of the company’s common stock for the first quarter of 2021. Payment will be made on Jan. 8, 2021 to shareholders of record at the close of business on Dec. 15, 2020. About Merck For more than 125 years, Merck, known as MSD outside of the Unite

EmpiRx Health, the industry’s only value-based pharmacy benefit manager (PBM), today announced it has appointed David Busch as chief growth officer.

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the closing of its public offering of 2,990,000 shares of common stock